is a specialty section of Frontiers in Pharmacology and Frontiers in Psychiatry.
The section published major insights into animal and human psychopharmacology, as well as the neurobiological basis of behavior induces by psychotropics. We welcome papers concerned with the interplay between behavior and neurobiological analysis at all levels using psychotropics as tools including molecular biology, genetics, and morphological, biochemical, neurochemical, electrophysiological, neuroendocrinal and neuroimaging studies. While Psychopharmacology is primarily centered on animal behavior, human studies that can validate conclusions from animal research are also welcome. Work in all animal species, including humans, is welcome, and integrative and translational approaches combining animal and human research are encouraged. In recent years, translational work has proven to be particularly suitable to address topics and questions related to psychopathology, with outstanding examples showing how animal studies can help identify key genetic mechanisms of behavioral deviation in humans and, conversely, how innovative findings in humans are directing essential work in animals. Our ultimate goal is to accelerate the progress in this research area at a critical time when we are facing multiple challenges: from the need to integrate findings obtained at different levels of analysis to the constant redefinition of topics and approaches that concern and characterize the field of psychopharmacology.
welcomes submissions of the following tier 1 articles
: Book Review, Clinical Case Study, Clinical Trial, Editorial, General Commentary, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge and Technology Report.
All manuscripts must be submitted directly to the section Psychopharmacology
, where they are peer reviewed by the associate and review editors of the specialty section.
Articles published in the section Psychopharmacology
will be subject to the Frontiers evaluation system
after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a prestigious Frontiers Focused Review
- a tier 2 article. This is referred to as "democratic tiering
". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Pharmacology and Psychiatry.